INTRODUCTION
The human immunodeficiency virus (HIV) induces profound disturbances in cellular and humoral immunity, both at the specific and non-specific levels (Fauci et al., 1996) . Typically, untreated HIV-infected individuals experience disease progression and manifest hypergammaglobulinemia with antibodies (Abs) to core and surface components of HIV, but lack specific neutralizing anti-HIV envelop Abs and specific recall Abs to naturally encountered or vaccine delivered antigens (Ag) (Amadori and Chieco-Bianchi, 1990) . A classic feature of HIV-disease progression is the consistent destruction of lymph nodes (LN) contributing to the progressive loss of the CD4 þ T-cell compartment-the hallmark of HIV infection and AIDS (Richard et al., 2002) .
Management of HIV-infected individuals in Africaand particularly in poor countries-represents a real challenge. Few strategies are in place in tropical Africa, and while the introduction of antiretroviral drugs is planned, only vaccination strategies can truly represent a chance to limit infection spreading (Marcus et al., 2002) .
Whether these vaccines are expected to be preventive or therapeutic, their ultimate goal is to limit viral replication to favor the expansion of specific cytolytic T cells (CTLs) and induce B cells to produce neutralizing Abs (Peters, 2001) . These strategies may be reinforced with the help of an intact innate immune system (Siegal and Spear, 2001) .
In the present study, we characterized the peripheral B cell compartment of 15 drug-naive HIV-infected individuals. At homeostasis or in disease states that do not affect LN architecture or bone marrow production, blood B cells are comprised of naive and non-naive (mostly memory) B lymphocytes which recirculate, especially after antigenic exposure. These B cells represent a milestone of the specific infection they defend against as they differentiate into (neutralizing) Ab-secreting cells and, therefore are targets of vaccination strategies. Indeed, the presence of circulating cells assumed to be plasmocytes-capable of secreting anti-HIV Abs-has been reported in HIV þ patients; these studies examined treated Americans or untreated, Europeans with low viral load, respectively (Marcus et al., 2002; Richard et al., 2002) . In the present work, we studied a group of HIV-infected individuals living in Central Africa, and unexpectedly observed germinal center (GC) originating-B lymphocytes (not plasmocytes) circulating in the periphery. This observation may impact future vaccination strategies.
MATERIALS AND METHODS

Patients
African donors were consultants at the "Hôpital Communautaire" of Bangui, Central African Republic (CAR) as spouses of hospitalized patients with AIDS. The prevalence of HIV-infection in CAR is estimated to be 12.9% of the adult population (UNAIDS/WHO 2002). All donors enrolled in this study were informed and consented to donate blood for research purposes, according to the rules of the ad hoc Ethics Committee set up by the Institut Pasteur in Bangui, in the absence of a National Ethics Committee. None of the blood donors were previously diagnosed with HIV infection, and all were indeed antiretroviral drug-naive. Patients were selected on the basis of African AIDS symptoms defined by the WHO at Bangui in 1985 (Diagnosing symptomatic HIV infection and AIDS in adults, 1993). Approximately 10 ml of heparinized blood was obtained from a series of individuals and 15 were diagnosed HIV þ . HIV serology was routinely followed in Bangui using the Vironostika HIV-Uniform II plus O test (Organon Teknika, Durham, NC) . Plasma viral load (VL), determined in Saint-Etienne using a nested PCR technique as previously described (Peters, 2001) , ranged from 10,000 to 80,000 copies/ml. HIV-1 clades A predominate in Bangui (Muller-Trutwin et al., 1999) . Matched controls consisted of 9 HIVnegative patients African PBMC samples.
In order to compare certain biological parameters, the phenotype of blood B cells from European volunteer blood donors was also tested in this survey. Informed consent was obtained from the European patients according to the requirements of the National French Ethics. There were 30 HIV þ European blood donors followed by the Department of Infectious Diseases at the University Hospital in Saint Etienne, France. Approximately 10 ml of heparinized blood was obtained specifically for the present study. All patients enrolled in this study were treated with antiretroviral drugs according to current protocols and were monitored for clinical and biological parameters for disease progression. Plasma VL was routinely monitored in patients over time. At the time of sampling for the present work, 28/30 patients had VL of less than 50 copies/ml. Matched controls consisted of 9 HIV-negative patients European PBMC samples.
T and B Cell Phenotyping
Standard T (CD4 þ ) cell phenotyping was performed extemporarily at the Institut Pasteur in Bangui. Lymphocyte subsets were analyzed on a FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA) with two monoclonal antibodies (MAbs) (aCD4 -aCD8, Becton Dickinson Immunocytometry Systems).
The extended B cell phenotyping was performed in Saint-Etienne. PBMCs, stored in Stabilcytee (BioErgonomics, St Paul, MN) in Africa, were stained with the following mAbs conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE) or RPE-Cy5 suitable for three-color flow cytometry. The following markers were used: CD20-RPECy5, IgD-FITC, IgM-PE, CD38-FITC, CD38-PE, CD27-PE (all from DAKO, Copenhaguen, Denmark); CD77-FITC (BD-Pharmingen, San Diego, CA); CD138-PE (Coulter-Immunotech, Marseille, France). Ig isotype-matched FITC-, PE-and RPECy5-conjugated mouse Ab (DAKO) were used as negative controls to test for non-specific staining. Briefly, 0.5 £ 10 6 cells were stained with the appropriate mAb for 45 min on ice. Afterwards, the cells were washed in PBS with 10% fetal calf serum and fixed in PBS containing 4% paraformaldehyde. Flow cytometry was performed on the following day using a FacsVantage-SF BD and the CellQuest-Proe software (Becton-Dickinson, San-Jose, CA).
Statistics
Means^SEM of data between the blood donor groups were compared using the Mann -Whitney test. Statistical analysis was performed using the Statviewe software (SAS Institute INC, Cary, NJ).
RESULTS
African Blood Donor Group
The design of the present survey, i.e. the study of blood B cell of volunteer, HIV-infected African individuals unaware of their infection, living with AIDS-spouses, has considerably limited the size of this cohort. The initial serological test performed on blood samples for each volunteer defined two groups (HIV þ and HIV 2 ). Newly recognized HIV þ individuals were informed of their serological status, counseled by the physician at the hospital and entered into the specific HIV program at the clinics. The mean CD4 þ T cell count^SEM was 316.6^65.6 cells/ml for the 15 HIV þ individuals and 913^66 cells/ml for the 11 HIV 2 individuals; P ¼ 0.0007) ( Table I) . As very few of the recently diagnosed patients were hospitalized (except #6 and #8) for various reasons (including economical), we were unable to perform CDC staging.
Major Characteristic of Circulating B Cells in HIVinfected African Blood Donors
The HIV þ African blood donors presented lower B cell counts than the HIV 2 Africans. The % mean of CD20 þ B cell count^SEM was 4.9^0.7 for the 15 HIV þ individuals and 6.7^0.6 for the 9 HIV 2 individuals;
A careful examination of the B cell subpopulation phenotype was then carried out by 3 color-flow cytometry. We first determined the relative proportions of naive and non-naive circulating blood B cells on the basis of their reactivity with anti-CD20 and anti-IgM^anti-IgD fluorescent-dye labeled Abs. As shown in Fig. 1,  CD20 þ , surface-(s)IgM þ /sIgD þ cells assumed to be naive B cells (Banchereau and Rousset, 1992) Fig. 2A,B) Fig. 2B ).
DISCUSSION
In this study, we attempted to integrate observations on circulating B lymphocytes in HIV-infected drug-naive individuals. We tried to understand to what extent, and how, the B cell compartment, is affected by HIV-infection, especially in drug-naive patients which represent the majority of infected individuals worldwide. The next step would be to try to circumvent the B cell disorders and in so doing protect the B cell compartment to allow the development of protective-type Abs, awaiting an antidisease vaccine. The study population consisted of African individuals unique in four areas: (i) origin and genetic background; (ii) hyperactivation of the immune system by numerous infectious pathogens leading to the so-called tropical AIDS (Germani et al., 1998; Bentwich et al., 2000; Begaud et al., 2003) ; (iii) no access to antiretroviral treatment and insufficient access to health care and (iv) virus clade.
This and other studies have shown that HIV infection leads to profound alterations at the level of B cell homeostasis (Richard et al., 2002) . Although exacerbated plasmacytosis in bone marrow and in peripheral tissues have been consistently reported in HIV infection (Calenda and Chermann, 1992; Nagase et al., 2001) , no consensus has been reached on whether plasmocytes can circulate. We did not find circulating plasmocytes in our close examination of blood smears (data not shown). However, we found a fraction of circulating B lymphocytes phenotypically modified when compared to HIV-uninfected individuals, such as the reduction in CD27 þ memory-type B cells (De Milito et al., 2001 ). Certain studies aimed at characterizing the Ab secreting cell precursors found various phenotypic changes such as the low expression of CD21 (Moir et al., 2001) , CD23 (Rodriguez et al., 1996) , CD38, CD39, CD20, CD37, CD71 (Fournier et al., 2002) and modified expression of CD22, sIgM and sIgG molecules (Dawood et al., 1998) etc, suggesting that these cells could be early plasma cells originating from GCs (Forster et al., 1997) . Our study showed that African individuals had fewer naive
þ^s IgD 2 sIgM^) B cells compared to European individuals. This could be linked to the tropical environment where, for example, chronic parasite infections are known to affect the immune system. Multiparasitisme is indeed frequently observed in CAR (Begaud et al., 2003) . On the other hand, we found significantly more CD20 þ /CD77 þ B cells (CD77 being a phenotypic characteristic of centroblasts (Wiels, 2000) ) in HIV þ Africans compared to HIV-uninfected individuals or European patients. This second particularity seems to be directly associated with the evolution of HIV infection in African individuals and with the presence of the virus (high VL) in the absence of treatment. We also found elevated numbers of B cells expressing surface CD138 (a feature of post-GC B cells) (Wijdenes et al., 1996) . However, CD138 marker is imprecisely known, rendering this staining difficult to interpret. Taken together, our findings strongly suggest that the unexpected circulating B cells share the features of GC-(Bm3s and Bm3) and post-GC-B cells (Liu et al., 1996) . In vivo, such lymphocytes may have received progression and differentiation signals and/or may be pre-switched. They may differentiate terminally in bone marrow and in tissue-associated lymphoid organs, and some may possibly be aberrantly located as a result of HIV-infection (Forster et al., 1997) . It is not clear, however, that these GC cell subsets differentiate in vivo and in vitro (our unpublished observations) as we have not yet specifically identified a population ascribed to a centrocytic phenotype. Our data agrees with several studies on the architectural disturbance of the LN in HIV-infection, AIDS and HIV-associated Hodgkin and non-Hodgkin lymphomas (Clarke and Glaser, 2001) . Further, it has been reported that disruption of GCs blocks the formation of B cell memory (Roy et al., 2002) which fits with the present observation. Our study may also suggest that the hypergammaglobulinemia observed during HIV-infection at least partly reflects the disorganization of LNs and particularly GCs, which may prematurely release into the periphery GC-and post-GC-B lymphocytes poised to differentiate terminally. Our study differs from other studies in that we have enrolled African patients who were heavily infected with HIV. Our observations focused on the direct relationship between peripheral B cell subset imbalances and LN disorganization, and the absence of treatment (and the absence of viral control). The architectural disorganization of the LN-along with the aberrant release of early plamocytes by the bone marrow-seems largely responsible for the B cell dysregulation observed during HIV-infection progression in African countries. This strongly argues for the establishment of therapeutic vaccines trials as we await the implementation of drug treatment programs.
